Information for Patients & Healthcare Professionals:

Revlimid[®] (lenalidomide) is structurally related to thalidomide and is expected to cause severe birth defects or death to an unborn baby therefore:

- Female patients of childbearing potential must always use effective contraception
- Female patients of childbearing potential must have pregnancy tests every 4 weeks, prior to each prescription, to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation
- Male patients with pregnant partners or partners of childbearing potential not using
 effective contraception must always use condoms (even if man has had a vasectomy)
 If a female patient or female partner of a male patient suspects they are pregnant.
- If a remain patient or leman partner or a male patient suspects they are pregnant they must contact their prescriber immediately
- You MUST tell your prescriber immediately if you experience any symptom that causes concern.

For complete information on the side effects of lenalidomide, patients should read the Package Leaflet and Healthcare professionals should read the Summary of Product Characteristics.

Date of preparation of text: April 2022 Approved by MHRA: November 2022 2003-GB-2200039 Version 10

Information for Healthcare Professionals:

Prescription Details

Has the patient received counselling?:	Yes No
Childbearing potential assessment:	WCBP / WNCBP / Male
If the patient is a WCBP is she using effective contraception?:	Yes No
If the patient is male, is he using condoms, if required?:	Yes No

Information for Healthcare Professionals:

Prescription Details

This patient is receiving lenalidomide for treatment of:
Multiple Myeloma or
Myelodysplastic Syndromes or
Mantle Cell Lymphoma or
Follicular Lymphoma

A completed Prescription Authorisation Form must accompany each prescription to confirm that the patient continues to use effective contraception (if required) and, in the case of a WCBP, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant.

Emergency contact information:

Date of preparation of text: April 2022

Approved by MHRA: November 2022

ergency Prescriber Contact:
phone number during office hours:
phone number after office hours:
information is available in the patient brochure.

2003-GB-2200039

Version 10